Perioperative Management of Oral Anticoagulation

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 299-309

  O'Donnell, Martin ^a   Kearon, Clive ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; DRUG INDICATION; HEART ARREST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; SURGICAL RISK; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; PERIOPERATIVE CARE; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; VENA CAVA FILTERS; VENOUS THROMBOSIS; WARFARIN;

EID: 41749124558     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.012     Document Type: Review

References (71)

1. Kearon C., and Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 336 21 (1997) 1506-1511
2. Heit J.A. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombolysis 12 (2002) 81-87
3. Ansell J.E. The perioperative management of warfarin therapy. Arch Intern Med 163 (2003) 881-883
4. Dunn A.S., and Turpie A.G. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 163 (2003) 901-908
5. Ansell J., Hirsh J., Dalen J., et al. Managing oral anticoagulant therapy. Chest 119 (2001) 22S-38S
6. Halperin J.L. Anticoagulation for atrial fibrillation in the elderly. Am J Geriatr Cardiol 14 2 (2005) 81-86 Review
7. Douketis J.D., Kearon C., Bates S., et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279 (1998) 458-462
8. Geerts W.H., Pineo G., Heit J.A., et al. Prevention of venous thromboembolism. Chest 126 (2004) 338S-400S
9. White R.H., McKittrick T., Hutchinson R., et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 122 (1995) 40-42
10. Tinmouth A.H., Morrow B.H., Cruickshank M.K., et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 35 (2001) 669-674
11. Kovacs M., Kearon C., Rodger M., et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 110 12 (2004) 1658-1663
12. Douketis J.D., Johnson J.A., and Turpie A.G. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 164 12 (2004) 1319-1326
13. Dunn A.S., Spyropoulos A.C., and Turpie A.G. Bridging therapy in patients with long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort trial (PROSPECT). J Thromb Haemost 5 11 (2007) 2211-2218
14. Wells P.S., Kovacs M.J., Bormanis J., et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 158 16 (1998) 1809-1812
15. Spandorfer J.M., Lynch S., Weitz H.H., et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 84 (1999) 478-480 A10
16. Turpie A.G.G., and Johnson J. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (Dalteparin). Circulation 102 (2002) II-826 (abstract 3983)
17. O'Donnell M., Kearon C., Johnson J., et al. Prevalence of residual anticoagulant activity following bridging low molecular weight heparin. Ann Intern Med 146 3 (2007) 184-187
18. Becker R.C., Spencer F.A., Gibson M., et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143 (2002) 753-759
19. Douketis J.D., Kinnon K., and Crowther M.A. Thromboprophylaxis with twice-daily but not with once-daily low-molecular-weight heparin is associated with a detectable anticoagulant effect at time of epidural catheter removal in patients receiving co-administered continuous epidural analgesia. Thromb Haemost 88 1 (2002) 37-40
20. Wahl M.J. Dental surgery in anticoagulated patients. Arch Intern Med 158 (1998) 1610-1616
21. Sindet-Pederson S., Ramstrom G., Bernvil S., et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 320 (1989) 840-843
22. McCormack P., Simcock P.R., and Tullo A.B. Management of the anticoagulated patient for ophthalmic surgery. Eye 7 Pt 6 (1993) 749-750
23. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 48 (1998) 672-675
24. Tinker J.H., and Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: observations in 180 operations. [abstract]. JAMA 239 (1978) 738-739
25. Francis C.W., Marder V.J., Evarts C.M., et al. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 249 (1983) 374-378
26. Taberner D.A., Poller L., Burslem R.W., et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1 (1978) 272-274
27. Rustad H., and Myhre E. Surgery during anticoagulant treatment: the risk of increased bleeding in patients on oral anticoagulant treatment. [abstract]. Acta Med Scand 173 (1963) 115-119
28. Francis C.W., Pellegrini Jr. V.D., Leibert K.M., et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 75 (1996) 706-711
29. Hylek E.M., Regan S., Go A.S., et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 135 6 (2001) 393-400
30. Crowther M.A., Julian J., McCarty D., et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 356 (2000) 1551-1553
31. Shields R.C., McBane R.D., Kuiper J.D., et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 76 (2001) 260-266
32. Bonow R.O., Carabello B., de Jr. L.A., et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98 (1998) 1949-1984
33. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized trials. Arch Intern Med 154 (1994) 1449-1457
34. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med 158 (1998) 1316-1320
35. Hart R.G., and Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 131 (1999) 688-695
36. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation. Chest 126 (2004) 429S-456S
37. Mok C.K., Boey J., Wang R., et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 72 (1985) 1059-1063
38. Cannegieter S.C., Rosendaal F.R., and Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89 2 (1994) 635-641
39. Horstkotte D., Scharf R.E., and Schultheiss H.P. Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis 4 (1995) 114-120
40. Salem D.N., Stein P.D., Al-Ahmad A., et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 126 (2004) 457S-482S
41. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993) 1255-1262
42. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 126 (2004) 401S-428S
43. Berge E., Abdelnoor M., Nakstad P.H., et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 355 (2000) 1205-1210
44. Hart R.G., Palacio S., and Pearce L.A. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 33 (2002) 2722-2727
45. Bath P.M., Lindenstrom E., Boysen G., et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 358 (2001) 702-710
46. Bath P.M., Iddenden R., and Bath F.J. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 31 (2000) 1770-1778
47. Saxena R., Lewis S., Berge E., et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with accute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 32 10 (2001) 2333-2337
48. Collins R., Peto R., Baigent C., et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336 (1997) 847-860
49. Chan W.S., Anand S., and Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160 (2000) 191-196
50. Salazar E., Izaguirre R., Verdejo J., et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 27 (1996) 1698-1703
51. Montalescot G., Polle V., Collet J.P., et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 101 (2000) 1083-1086
52. Douketis J.D., Crowther M.A., and Cherian S.S. Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey. Can J Cardiol 16 (2000) 326-330
53. Douketis J.D., Crowther M.A., Cherian S.S., et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 116 (1999) 1240-1246
54. Garcia D.A., Ageno W., Libby E.N., et al. Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. J Thromb Thrombolysis 18 3 (2004) 199-203
55. Garcia D.A., Regan S., Henault L.E., et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 168 1 (2008) 63-69
56. Ginsberg J.S., Chan W.S., Bates S.M., et al. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 163 (2003) 694-698
57. Coon W.W., and Willis P.W. Recurrence of venous thromboembolism. Surgery 73 (1973) 823-827
58. Heit J.A., Mohr D.N., Silverstein M.D., et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160 (2000) 761-768
59. Hull R., Raskob G., Pineo G., et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329 (1993) 1370-1376
60. Colwell Jr. C.W., Collis D.K., Paulson R., et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone Joint Surg 81-A (1999) 932-940
61. Hull R.D., Raskob G.E., Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322 (1990) 1260-1264
62. Collins R., Scrimgeour A., Yusuf S., et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 318 (1988) 1162-1173
63. Kakkar V.V., Cohen A.T., Edmonson R.A., et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341 (1993) 259-265
64. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 119 (1993) 874-881
65. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001) 64S-94S
66. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338 (1998) 409-415
67. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126 (1997) 133-136
68. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112 6 (1990) 423-428
69. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
70. Blackshear J.L., Baker V.S., Rubino F., et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 348 (1996) 633-638
71. Palareti G., and Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30 (1996) 300-313